This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Jonathan Gootenberg, PhD
Principal Investigator, Center for Vaccines and Virology Research at Beth Israel Deaconess Medical Center


Jonathan Gootenberg is a member of the faculty at Harvard Medical School and an investigator at Beth Israel Deaconess Medical Center. Dr. Gootenberg draws from fundamental biological insights to engineer new molecular tools, with a focus on methods that leverage programmability across biological scales. These technologies, including CRISPR-mediated genome and transcriptome perturbation and non-destructive cellular sensing, allow for unprecedented manipulation and profiling of cellular states in the body, and have myriad applications in basic science, diagnostics, and therapeutics. These technologies have been adopted by multiple biotechnology companies, several of which Dr. Gootenberg has co-founded.

Previously, Dr. Gootenberg led an independent research group at MIT as a McGovern Fellow. He received his PhD in Systems Biology from Harvard University, conducting research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT and Harvard, and earned his bachelor’s degree in mathematics and biological engineering at MIT. He has been honored with awards such as Forbes 30 Under 30, Technology Review 35 Under 35, Endpoints 20 Under 40, and as a scholar of the Termeer Foundation.

Agenda Sessions

  • Programmable Molecular Technologies for Genome Editing and Cell Control